54 completed, 10 recruiting, 9 terminated, 6 unknown. 23 Phase 4, 22 Phase 3, 21 Phase 2, 6 Phase 1, 5 Not applicable.
Follow Eliquis: new trials by email Literature Review of Eliquis trials Research Report on Eliquis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Strategies for the Management of Atrial Fibrillation in patiEnts Receiving Dialysis 2 (SAFE-D2) Eliquis, No oral anticoagulation - Atrial Fibrillation, Atrial Flutter | Phase 3 | Not yet recruiting | Unity Health Toronto | 848 | 2026-11-01 | 2026-08-21 |
| SWITCH: Apixaban vs Vitamin K in HM3 Warfarin, Apixaban - LVAD (Left Ventricular Assist Device) Thrombosis, Heart Failure | Phase 3 | Recruiting | Columbia University | 460 | 2026-10-15 | 2026-11-04 |
| Effect of Two Weeks of Low-Dose Apixaban on Platelet Reactivity in Patients With Stable Coronary Artery Disease on Dual Antiplatelet Therapy (Aspirin and Clopidogrel) Apixaban - Coronary Artery Disease, High On-treatment Platelet Reactivity (HTPR) | Phase 4 | Active not recruiting | The University of The West Indies | 16 | 2026-09-03 | 2026-10-02 |
| Extended Prophylactic Anticoagulation Following Spinal Surgery for Metastatic Disease Apixaban - Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT) | Phase 4 | Not yet recruiting | James Bayley | 50 | 2026-08-01 | 2026-07-20 |
| Net Clinical Benefit of Edoxaban Versus Apixaban in Patients With Atrial Fibrillation and Coronary Artery Disease Edoxaban, Apixaban - Atrial Fibrillation (AF), Coronary Arterial Disease (CAD) | Phase 4 | Recruiting | Samsung Medical Center | 3000 | 2026-07-20 | 2026-08-10 |
| BEACON-AA: Apixaban With or Without Clopidogrel in Stroke Patients With Atrial Fibrillation and Cerebral Atherosclerosis Apixaban, Clopidogrel - Stroke, Ischemic | Phase 4 | Recruiting | Yonsei University | 586 | 2026-07-14 | 2026-10-16 |
| Apixaban Versus Enoxaparin for Postpartum Venous Thromboembolism Prophylaxis Apixaban, Enoxaparin - Postpartum, DVT Prophylaxis | Not applicable | Not yet recruiting | Ron Beloosesky MD | 150 | 2026-07-01 | 2026-07-21 |
| Apixaban to Prevent Venous Thromboembolism in Ambulatory Lung Cancer Patients Undergoing Systemic Anticancer Treatment Apixaban, Placebo - Thromboprophylaxis | Phase 3 | Recruiting | University of Birmingham | 1456 | 2026-04-28 | 2026-09-28 |
| Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation REGN7508, REGN9933, Apixaban - Atrial Fibrillation (AF) | Phase 2 | Recruiting | Regeneron Pharmaceuticals | 1200 | 2025-10-20 | 2026-11-05 |
| Treatment With Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus After Acute Myocardial Infarction Apixaban, Warfarin - Left Ventricular Thrombus, Acute Myocardial Infarction | Phase 4 | Recruiting | Karolinska Institutet | 212 | 2025-04-08 | 2025-07-01 |
| Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies Apixaban, Rivaroxaban, low molecular weight heparin (enoxaparin sodium) - Lymphoma, Leukemia | Not applicable | Recruiting | Medical University of Gdansk | 100 | 2024-11-22 | 2025-12-26 |
| A Trial to Learn How Well REGN9933 Works for Preventing Blood Clots After Knee Replacement Surgery in Adult Participants REGN9933, Enoxaparin, Apixiban - Venous Thromboembolism | Phase 2 | Completed | Regeneron Pharmaceuticals | 373 | 2023-05-24 | 2025-08-29 |
| A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE Abelacimab, Apixaban - Venous Thromboembolism, Deep Venous Thrombosis | Phase 3 | Terminated | Anthos Therapeutics, Inc. | 1150 | 2022-05-05 | 2026-02-23 |
| Apixaban Prevents Portal Vein Thrombosis After Laparoscopic Splenectomy and Azygoportal Disconnection Apixaban 2.5 MG, Dipyridamole 25Mg Tab, subcutaneous Low Molecular Weight Heparin - Cirrhosis, Splenectomy | Not applicable | Completed | Northern Jiangsu People's Hospital | 40 | 2022-04-01 | 2023-12-21 |
| DOAC Versus VKA After Cardiac Surgery Warfarin, Dabigatran, Rivaroxaban - Anticoagulant-induced Bleeding | Phase 2 | Withdrawn | Laval University | 2022-03-09 | 2023-03-13 | |
| COmparison of Bleeding Risk Between Rivaroxaban and Apixaban in Patients With Atrial Fibrillation Apixaban, Rivaroxaban - Atrial Fibrillation | Phase 4 | Recruiting | Ottawa Hospital Research Institute | 3018 | 2021-07-06 | 2026-10-01 |
| Direct Oral Anticoagulants (Rivaroxaban and Apixaban) in Patients With Liver Cirrhosis Rivaroxaban 10 mg Oral Tablet, Apixaban 2.5 mg Oral Tablet - Liver Cirrhosis | Phase 1 | Recruiting | Insel Gruppe AG, University Hospital Bern | 24 | 2021-05-19 | 2026-08-19 |
| Prediction of the COBRRA AF Anticoagulant Trial in Healthcare Claims Data Rivaroxaban, Apixaban - Atrial Fibrillation | Completed | Brigham and Women's Hospital | 353980 | 2021-05-03 | 2025-03-04 | |
| Prediction of the COBRRA VTE Anticoagulant Trial in Healthcare Claims Data Rivaroxaban, Apixaban - Venous Thromboembolism, Pulmonary Embolism | Completed | Brigham and Women's Hospital | 41875 | 2021-05-03 | 2023-07-27 | |
| A Prospective Multi-dose Study of Apixaban in Subjects With Nephrotic Syndrome Apixaban 5 MG - Nephrotic Syndrome, Membranous Nephropathy | Phase 1 | Completed | University of North Carolina, Chapel Hill | 22 | 2021-04-14 | 2023-09-26 |
Showing 20 of 88. Sign in to see all of them.
Atrial Fibrillation (22) · Venous Thromboembolism (19) · Venous Thrombosis (14) · Pulmonary Embolism (10) · Stroke (9) · Thrombosis (7) · Hemorrhage (6) · Ischemic Stroke (6) · Cerebral Hemorrhage (4) · Kidney Failure, Chronic (4) · Neoplasms (4) · Nephrotic Syndrome (3) · Atrial Flutter (2) · Fibrosis (2) · Glomerulonephritis, Membranous (2)
Bristol-Myers Squibb (9) · Ottawa Hospital Research Institute (5) · Mayo Clinic (4) · Academic and Community Cancer Research United (2) · Brigham and Women's Hospital (2) · Columbia University (2) · Northern Jiangsu People's Hospital (2) · Regeneron Pharmaceuticals (2) · Thomas Jefferson University (2) · Unity Health Toronto (2) · University of North Carolina, Chapel Hill (2) · Alliance Foundation Trials, LLC. (1) · Anthos Therapeutics, Inc. (1) · Asan Medical Center (1) · Atrial Fibrillation Network (1)
United States (36) · Canada (19) · Germany (8) · United Kingdom (8) · Spain (7) · South Korea (6) · Italy (5) · Switzerland (5) · Australia (4) · Belgium (4) · China (4) · France (4) · Norway (4) · Austria (3) · Hungary (3)
Lana Castellucci, MD, FRCPC (3) · Daniel Crona, PharmD, PhD (2) · Robert D McBane (2) · Samuel Asirvatham, MD (2) · Shirley Wang, PhD, ScM (2) · Aaron S Weinberg, MD (1) · Agnes YY Lee, MD MSc FRCPC (1) · Anders EA Dahm, MD, PhD (1) · Aurelien Delluc, MD, PhD (1) · Bao-Huan Zhou, MS (1) · Brent Petty (1) · Catharina JM Klijn, MD PhD (1) · Christopher DeSimone, MD (1)
PMID 36700520, PMID 34022170, PMID 34172290, PMID 42389777, PMID 10582984, PMID 10905241, PMID 17258667, PMID 17272772, PMID 17332445, PMID 17525387, PMID 17702958, PMID 18388338, PMID 19590057, PMID 19764826, PMID 20075341, PMID 21030700, PMID 21719764, PMID 22932714, PMID 22932715, PMID 23390923, PMID 23920012, PMID 24424332, PMID 28837207, PMID 30206088, PMID 30462279, PMID 30511879, PMID 30997117, PMID 31002997, PMID 31243691, PMID 31421933, PMID 31606897, PMID 31610718, PMID 31630479, PMID 32476465, PMID 32589230, PMID 32641236, PMID 32766953, PMID 32919178, PMID 33242339, PMID 33337539, PMID 3363593, PMID 33857789, PMID 34487722, PMID 34622445, PMID 34662890, PMID 34687635, PMID 35124234, PMID 35135065, PMID 35439353, PMID 35660801
2014 (3), 2016 (2), 2015 (1), 2018 (1), 2023 (1), P30CA015083 (1), U01NS095869 (1), U01NS106513 (1)